1. Home
  2. IMVT

IMVT

Immunovant Inc.

Logo Immunovant Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Founded: N/A Country:
United States
United States
Employees: 164 City: NEW YORK
Market Cap: 4.3B IPO Year: N/A
Target Price: $44.67 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 18
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.83 EPS Growth: N/A
52 Week Low/High: $14.11 - $45.58 Next Earning Date: 05-20-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: